Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.05M | 15.70M | 16.05M | 17.40M | 17.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.43M | 44.30M | 41.48M | 40.43M | 36.17M |
| Operating Income | -50.43M | -44.30M | -41.48M | -40.43M | -36.17M |
| Income Before Tax | -80.77M | -56.90M | -48.90M | -60.61M | -56.74M |
| Income Tax Expenses | 3.21M | 75.00K | 134.00K | 103.00K | 87.00K |
| Earnings from Continuing Operations | -83.98 | -56.98 | -49.03 | -60.71 | -56.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.98M | -56.98M | -49.03M | -60.71M | -56.83M |
| EBIT | -50.43M | -44.30M | -41.48M | -40.43M | -36.17M |
| EBITDA | -50.29M | -44.18M | -41.32M | -40.25M | -35.98M |
| EPS Basic | -16.44 | -12.20 | -10.98 | -13.97 | -13.14 |
| Normalized Basic EPS | -8.72 | -6.50 | -6.35 | -5.50 | -4.90 |
| EPS Diluted | -16.44 | -12.20 | -10.98 | -13.97 | -13.14 |
| Normalized Diluted EPS | -8.72 | -6.50 | -6.35 | -5.50 | -4.90 |
| Average Basic Shares Outstanding | 20.03M | 18.84M | 17.76M | 17.40M | 17.30M |
| Average Diluted Shares Outstanding | 20.03M | 18.84M | 17.76M | 17.40M | 17.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |